1159599-99-1

Basic information

• Product Name: 2-oxa-6-azaspiro[3,3]heptane oxalic acid salt
• Synonyms: 2-Oxa-6-azaspiro[3.3]heptane ethanedioate;2-Oxa-6-azaspiro[3.3]heptane oxalate;2-Oxa-6-azaspiro[3.3]heptane, ethanedioate (1:1);2-oxa-6-azaspiro[3.3]heptane, hemioxalate salt;2-oxa-6-azaspiro[3.3]heptane (Form: oxalate);2-oxa-6-azaspiro[3.3]heptan-6-ium carboxyformate;2-oxa-6-azaspiro[3,3]heptanes hemioxalate
• CAS NO: 1159599-99-1
• Molecular Formula: C₂H₂O₄*C₅H₉NO
• Molecular Weight: 189
• Mol File: 1159599-99-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2-oxa-6-azaspiro[3,3]heptane oxalic acid salt(CAS DataBase Reference)
• NIST Chemistry Reference: 2-oxa-6-azaspiro[3,3]heptane oxalic acid salt(1159599-99-1)
• EPA Substance Registry System: 2-oxa-6-azaspiro[3,3]heptane oxalic acid salt(1159599-99-1)

Safety Data

• Hazardous Substances Data: 1159599-99-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Chemical Synthesis:
2-Oxa-6-azaspiro[3,3]heptane oxalic acid salt is used as an intermediate in the pharmaceutical and chemical synthesis industry. It plays a crucial role in the development of new drugs and chemical products by acting as a building block or a key component in the synthesis process.
Used in Medicine:
In the medical field, 2-Oxa-6-azaspiro[3,3]heptane oxalic acid salt is used for its potential therapeutic applications. Its specific uses may vary depending on the particular medical application, but it is generally recognized for its ability to contribute to the development of new treatments and therapies.

InChI:InChI=1S/C5H9NO.C2H2O4/c1-5(2-6-1)3-7-4-5;3-1(4)2(5)6/h6H,1-4H2;(H,3,4)(H,5,6)

Upstream product

• 13573-28-9 6-(p-toluenesulfonyl)-2-oxa-6-azaspiro[3.3]heptane 
• 174-78-7 2-oxa-6-azaspiro[3.3]heptane 
• 144-62-7 oxalic acid 
• 1522-92-5 2,2-bis(bromomethyl)-3-bromo-propan-1-ol 
• 78-71-7 3,3-bis(chloromethyl)oxetane 
• 2402-83-7 3,3-bis(bromomethyl)oxetane 
• 46246-91-7 2-benzyl-6-oxa-2-azaspiro[3.3]-heptane 

Downstream Products

• 1240402-44-1 {3-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-isoxazol-5-yl}-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-methanone 
• 1352621-28-3 (4-bromo-3-methylphenyl)(2-oxa-6-azaspiro[3.3]hept-6-yl)methanone 
• 1370444-27-1 2-[3-(3-chlorophenyl)-1-{4-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)ethyl]phenyl}-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]-N-(propan-2-yl)acetamide 
• 1449710-19-3 5-{2-[3-methoxy-4-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)phenyl]furo[3,2-b]pyridin-7-yl}-2-(tetrahydropyran-4-yloxy)benzonitrile 
• 1449279-91-7 N-((1S,2R)-2-hydroxy-3-oxo-1-phenyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)propyl)-benzamide 
• 1449279-92-8 tert-butyl (1S,2R)-2-hydroxy-3-oxo-1-phenyl-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-propylcarbamate 
• 1449279-89-3 (4S,5R)-(3-benzoyl-2-(4-methoxyphenyl)-4-phenyloxazolidin-5-yl)(2-oxa-6-azaspiro[3.3]heptan-6-yl)methanone 
• 1449279-90-6 (4S,5R)-tert-butyl-2-(4-methoxyphenyl)-4-phenyl-5-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)oxazolidine-3-carboxylate 
• 1549706-61-7 ethyl 1-(6-oxo-1-phenyl-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,6-dihydropyridazin-4-yl)-1H-1,2,3-triazole-4-carboxylate 
• 1549705-95-4 4-bromo-2-phenyl-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridazin-3(2H)-one 
• 1578244-77-5 N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-8-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrido[3,4-d]pyrimidin-2-amine 

Relevant articles and documents

SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY

The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Synthesis and Properties of 2-Oxa-6-azaspiro[3.3]heptane Sulfonate Salts

An improved synthesis of the bicyclic spiro compound 2-oxa-6-azaspiro[3.3]heptane is presented. While this compound is often isolated as an oxalate salt, its isolation as a sulfonic acid salt yields a more stable and more soluble product. With these improved properties access to a wider range of reaction conditions with the spirobicyclic 2-oxa-6-azaspiro[3.3]heptane has been enabled.

Design, synthesis and biological evaluation of novel azaspiro analogs of linezolid as antibacterial and antitubercular agents

The design, synthesis and antimicrobial evaluation of a novel series of azaspiro analogues of linezolid (1) have been described. Linezolid comprises of a morpholine ring which is known for its metabolism-related liabilities. Therefore, the key modificatio

The Development of a Manufacturing Route to an MCHr1 Antagonist

Process development work to provide an efficient manufacturing route to a MCHr1 antagonist is presented herewith. Features of this development work include a scalable manufacturing route to the useful 6-oxa-2-azaspiro[3.3]heptane building block and the use of a (soluble) alternative to sodium triacetoxyborohydride.

Design, synthesis and biological evaluation of paclitaxel-mimics possessing only the oxetane D-ring and side chain structures

Two spiro paclitaxel-mimics consisting only of an oxetane D-ring and a C-13 side chain were designed and synthesized on the basis of analysis of structure-activity relationships (SAR) of paclitaxel. In vitro microtubule-stabilizing and antiproliferative assays indicated a moderate weaker activity of the mimics than paclitaxel, but which still represented the first example of simplified paclitaxel analogues with significant anti-tumor biological activity.